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introduction: An increased expression of interferon (IFN)-responding genes (IRGs), 
the so-called IFN signature, has been reported in rheumatoid arthritis (RA). However, 
some controversy exists concerning its clinical relevance. The main aim of this study is 
to evaluate whether quantitative and qualitative differences in the activation of the IFN 
pathway may account for these findings.
Methods: The expression of IFN-induced protein 44 (IFI44), IFN-induced protein 44 
like (IFI44L), IFN alpha inducible protein 6, and MX dynamin-like GTPase 1 (MX1) was 
determined in peripheral blood in 98 RA patients (IFI6) and 28 controls. RA patients 
were classified into groups according to their clinical stage and treatments received: very 
early RA (VERA), biological disease-modifying antirheumatic drug (bDMARD) naive, and 
bDMARD. An additional group of 13 RA patients candidates for tumor necrosis factor 
alpha (TNFα) blockade was also recruited. The associations among IRGs were evaluated 
by network and principal component analyses.
results: The expression of all IRGs was increased in RA to different levels. The IFN 
score was increased in all RA groups (VERA, bDMARD-naïve, and bDMARD), but 
important differences in their degree of activation and in the relationships among IRGs 
were observed. The IFN score correlated with the accumulated disease activity score 
28-joints, and it was found to be a predictor of clinical outcome in VERA. No differences 
in the IFN score were observed between the bDMARD-naive and bDMARD groups, 
but opposite associations with the clinical parameters were noted. Interestingly, the 
correlations among IRGs delineate different pictures between these two groups. The 
IFN score at baseline predicted poor clinical outcome upon TNFα blockade. Although no 
absolute changes in the IFN score were found, TNFα-blockade shifted the associations 
among IRGs.
conclusion: A certain heterogeneity within the IFN signature can be recognized in RA, 
depending on the clinical stage. The structure of the IFN signature may be a potential 
explanation for the controversy in this field and must be considered to decipher its clinical 
relevancein RA.
Keywords: arthritis, interferon, iFn signature, biomarker, autoimmunity
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inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic systemic autoimmune 
condition hallmarked by joint inflammation and destruction. A 
number of immune mediators have been linked to RA patho-
genesis, including adaptive and innate components. A growing 
body of evidence supports an emerging role for type I interferons 
(IFNs) (1). Due to their immunomodulatory effects (2), the type 
I IFNs are thought to prompt the breakdown of tolerance and 
the subsequent perpetuation of autoimmune phenomena (3, 4). 
Actually, several IFN-related genes have been identified as risk 
loci for RA (3), and development of arthritis after treatment with 
IFNα has been extensively documented (5, 6).
Signaling through the type I IFN pathway leads to an increased 
expression of several IFN-responding genes (IRGs). This global 
expression profile, referred to as the “IFN signature,” has been 
found in peripheral blood in a subset of RA patients [from 25 
to 65% (7–10)]. Moreover, increased serum levels of IFNα have 
been demonstrated in RA (11). Elevated IFNα serum levels in the 
synovial fluid and IFN signature in the synovial membrane have 
also been reported (8, 12).
Although the potential role of the type I IFN as biomarkers has 
been investigated with enormous interest, the findings reported 
until date are contradictory and the current evidence is limited. 
On the one hand, inconclusive results of the association between 
the IFN score and clinical features have been reported (9, 10, 13, 
14). On the other hand, longitudinal changes of the IFN score 
have been described, partly attributed to the use of different 
immunomodulatory drugs (15–17). In addition, the majority 
of the studies were focused on patients with established disease, 
whereas a major knowledge gap exists for the role of the IFN sig-
nature in (very) early RA. Finally, a physiological diversification 
of the type I IFN response in different autoimmune diseases has 
been described, hence suggesting that different pathogenic roles 
for the type I IFNs may be expected in different clinical contexts 
(18). However, whether this can be applied to a single disease 
remains unknown.
Therefore, it is tempting to speculate that not only the degree 
of activation but also the composition of the IFN response could 
be relevant for its role as a biomarker. Taken all these ideas into 
account, we hypothesized that certain heterogeneity within 
the type I IFN signature in RA may impair its applicability as a 
biomarker, hence explaining the controversy reported in previ-
ous works. Thus, in this study, we aimed to analyze the potential 
associations between the IFN score and clinical features in RA 
patients depending on their clinical stage [from very early RA 
(VERA) to established disease], with a focus on the relationships 
among IRGs.
MaTerials anD MeThODs
ethical approval
The study was approved by the Institutional Review Board (Comité 
de Ética de Investigación Clínica del Principado de Asturias) in 
compliance with the Declaration of Helsinki. All study subjects 
gave written informed consent.
Patients and controls
Our study involved 98 RA patients [2010 ACR/European league 
against rheumatism (EULAR) classification criteria] recruited 
from the Department of Rheumatology at Hospital Universitario 
Central de Asturias. A complete clinical examination, including 
disease activity score 28-joints (DAS28) and health assessment 
questionnaire (HAQ) calculations, was performed on all patients 
during the clinical appointment. Patients recruited at onset and 
not being previously exposed to any treatment were considered as 
VERA. These patients were prospectively followed up for 1 year, 
and clinical outcomes were registered at 6 and 12 months. DAS28 
score accumulated over 1 year was calculated (19). Clinical man-
agement was performed according to EULAR recommendations 
(20). In addition, a group of 13 biologicals-naive RA patients [12 
women; median age, 43 (range, 30–65), DAS28 5.08 (1.93), 38.5% 
RF+, 46.1% ACPA+], candidates for tumor necrosis factor alpha 
(TNFα)-blockers was prospectively followed up for 3  months. 
A blood sample was obtained before and 3  months after the 
initiation of the TNFα blockade therapy. The clinical response 
was evaluated by EULAR criteria (21). Patients exhibiting a good 
response were compared to those with moderate or no response.
Simultaneously, 28 gender- and age-matched healthy controls 
(HCs) were recruited from the same population. A blood sample 
was collected from all individuals by venipuncture.
rna isolation and rT-Pcr
Blood samples were immediately processed after extraction. 
Whole blood was stabilized with RNA Stabilization Reagent for 
Blood/Bone Marrow (Roche, Germany) according to the manu-
facturer’s instructions and stored at −20°C. Then samples were 
thawed at room temperature, and mRNA was isolated using the 
mRNA Isolation Kit for Blood/Bone Marrow (Roche), according 
to the protocol provided by the manufacturer. Reverse transcrip-
tion was carried out using Transcription First Strand cDNA 
Synthesis Kit (Roche).
real-time Pcr
Gene expression was evaluated with TaqMan pre-designed 
assays for the following genes: IFN-induced protein 44 (IFI44; 
ref. Hs00197427_m1), IFN-induced protein 44 like (IFI44L; 
ref. Hs00915292_m1), MX dynamin-like GTPase 1 (MX1; ref. 
Hs00895608_m1), and IFN alpha inducible protein 6 (IFI6; ref. 
Hs00242571_m1). Reactions were performed in TaqMan® Gene 
Expression Master Mix. Real-time quantitative PCR was per-
formed in an ABI Prism HT7900 (Applied Biosystems, Germany) 
Abbreviations: ACPA, anticitrullinated peptide antibodies; bDMARDs, biological 
DMARDs; CRP, C-reactive protein; csDMARDs, conventional synthetic DMARDs; 
DAS28, disease activity score 28-joints; DMARDs, disease-modifying antirheu-
matic drugs; EULAR, European league against rheumatism; ESR, erythrocyte sedi-
mentation rate; HAQ, health assessment questionnaire; HC, healthy control; IFI6, 
interferon alpha inducible protein 6; IFI44, interferon-induced protein 44; IFI44L, 
interferon-induced protein 44 like; IFN, interferon; IRG, interferon-responding 
gene; MHC, major histocompatibility factor; MX1, MX dynamin-like GTPase 1; 
NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, 
rheumatoid factor; TNF, tumor necrosis factor alpha.
TaBle 1 | Characteristics of the subjects recruited in this study.
hc (n = 28) ra (n = 98) P value
Demographical features
Age (years);  
median (range)
49.38 
(35.17–60.17)
52.93 (22.00–65.10) 0.174
Gender (f/m) 20/8 79/19 0.334
Disease features
Disease duration (years) 4.00 (7.08)
Age at diagnosis (years);  
median (range)
47.37 (19.00–65.00)
Disease activity (DAS28) 4.01 (2.10)
Tender joint count 3.00 (7.00)
Swollen joint count 2.00 (5.00)
Patient global  
assessment (0–100)
50.00 (35.00)
Erythrocyte sedimentation  
rate (mm/h)
18.00 (29.00)
C-reactive protein (mg/l) 2.30 (4.50)
Health assessment  
questionnaire (0–3)
1.00 (1.16)
RF (+), n (%) 58 (59.1)
ACPA (+), n (%) 61 (62.2)
Erosive disease, n (%) 41 (41.8)
Treatments, n (%)
None 18 (18.3)
Glucocorticoids 56 (57.1)
Methotrexate 65 (66.3)
Tumor necrosis factor  
alpha blockers
36 (36.7)
Variables were summarized as median (interquartile range) or n (%), as appropriate, 
unless otherwise stated. Differences in demographic parameters were assessed by 
Mann–Whitney U-tests or χ2 tests, according to the distribution of the variables.
3
Rodríguez-Carrio et al. Type I IFN Signature in RA
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 2007
instrument, and Ct values were analyzed with the software SDS 
2.3. All samples were assayed by triplicate, and the average was 
used. Expression levels were evaluated by the 2−ΔCt method, using 
the GAPDH gene expression as the housekeeping to normalize Ct 
values. The expression levels were log transformed.
statistical analyses
Continuous variables were summarized as median (interquartile 
range) or mean ± SD, whereas n (%) was used for categorical ones. 
Differences between groups were analyzed by Mann–Whitney 
U-test, Kruskal–Wallis (with Dunn–Bonferroni correction for 
multiple comparisons), or χ2 tests, as appropriate. Wilcoxon test 
was used for paired samples. The size effect of the differences was 
evaluated by Hedges’g statistic (22). Correlations were assessed 
by Spearman ranks test. The associations of continuous variables 
adjusted for confounders were analyzed by multiple regression 
models, and B coefficients (B) with 95% confidence intervals 
(CIs) were calculated. The discriminative capacity was studied 
using receiving operator characteristics analyses, and the area 
under the curve (AUC) was computed. Z-scores were calculated 
for each IRG from the distribution found in the whole popula-
tion. Principal component analyses (correlation method) were 
performed with the individual IRGs, and biplots were generated 
to visualize the associations among IRG in the different groups 
of patients. Since strong correlations among IRGs were observed, 
an IFN score was calculated by averaging all IRGs per sample. 
P <  0.050 was considered as statistically significant. Statistical 
analyses were performed using SPSS 22.0, R 3.3.1 and GraphPad 
Prism 5.0 for Windows.
resUlTs
irg genes and iFn score: Quantitative 
and Qualitative approaches
To gain insight into the type I IFN signature in RA, the expression 
of IRGs, either independently or as a whole in a composite IFN 
score, was quantified in 98 RA patients and 28 HC (Table  1). 
All IRGs were upregulated in RA (Figure 1A), although a less-
pronounced difference was observed in IFI44. A composite IFN 
score was computed as previously described, and a higher value 
was found in RA (Figure 1A).
Importantly, certain heterogeneity among RA patients was 
observed. Therefore, we aimed to analyze whether the IFN score 
may differ according to the clinical stage of RA. Then patients 
were classified into three groups: VERA (patients recruited at 
onset, not being exposed to any treatment), biological disease-
modifying antirheumatic drug (bDMARD)-naive [patients on 
conventional synthetic DMARDs (csDMARD) treatment alone 
or in combination—glucocorticoids and/or methotrexate—not 
being previously exposed to any bDMARD], and bDMARD 
(patients on bDMARD therapy—all under TNFi treatment—with 
previous no response to csDMARD) (Table S1 in Supplementary 
Material). Although the IFN score was increased in all groups, 
quantitative differences were observed between VERA patients 
and their established counterparts (Figure 1B), hence indicating 
that the level of IRGs expression differed according to the disease 
course. No differences were found with the use of bDMARDs. 
Leukocyte populations did not exhibit notable differences among 
the groups analyzed (Table S2 in Supplementary Material). Only 
a slight increase in neutrophil count was observed in VERA 
patients. To exclude a potential confounding effect of the leuko-
cyte composition, the IFN score was corrected by the neutrophil-
to-lymphocyte ratio, and the differences among groups remained 
unchanged. Similarly, the IFN score did not correlate with any 
of the leukocyte populations nor in the whole RA population 
neither in the different clinical stages. Overall, a major effect of 
leukocyte composition on the IFN score can be ruled out.
Apart from quantitative differences, we aimed to evaluate 
whether qualitative differences, that is, distinct associations 
among IRGs, can be also found. To this aim, a PCA approach 
was conducted, and biplots were produced to visualize the 
potential associations among IRGs. First, a global PCA including 
all RA patients and HC was performed. Although a significant 
overlap was detected, differences were noted among groups 
(Figure 2A). The biggest differences were observed between HC 
and RA patients. The ellipse from VERA patients lie between 
those of HC and established RA groups. Again, IFI44 showed 
an outlier position in the graph compared to the rest of IRGs. 
However, certain dispersion was noted. It is important to note 
that differences observed in the IRGs expression and the distinct 
sample sizes could also limit a proper appraisal of the qualitative 
differences among groups. Therefore, additional analyses to gain 
insight into these differences were warranted.
FigUre 1 | Interferon (IFN)-responding gene (IRG) expression and IFN score in rheumatoid arthritis (RA) patients. (a) The expression of the individual IRGs 
[IFN-induced protein 44 (IFI44), IFN-induced protein 44 like (IFI44L), IFN alpha inducible protein 6 (IFI6), and MX dynamin-like GTPase 1 (MX1)] and the levels of the 
IFN score were compared between healthy control (HC) (gray boxes) and RA patients (white boxes). (B) The levels of the IFN score were compared between HC 
and RA patients according to the different clinical stages. Boxes represent 25th and 75th percentiles, whereas whiskers represent minimum and maximum values. 
Statistical analyses were performed by Kruskal–Wallis with Dunn–Bonferroni tests for multiple comparisons. P values correspond to those obtained in the multiple 
comparisons tests. For the analysis of individual IRGs, Hedges’g statistics (at the bottom of the graph) was included to account for the differential size effects 
observed across IRGs.
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Then independent biplots were generated for each group 
(Figure 2B). Based on the angles between the vectors of the IRGs, 
these analyses revealed that distinct pictures hallmarked the clini-
cal stages analyzed. First, remarkable differences were observed 
between HC and RA patients. Next, a distinct picture was found 
in the VERA group compared to both the bDMARD-naive and 
bDMARD groups, depending on the relative position of the 
IRGs. A shortening of the angles between IFI6 and MX1 as well 
as between IFI44 and IFI44L was seen in the established groups, 
especially in the bDMARD group. Furthermore, the associations 
among IRGs were plotted in correlation graphs (Figure 3A). This 
approach revealed that the associations among IRG were not 
homogeneous in the groups analyzed and, more importantly, 
IRGs exhibited a higher overall degree of correlation in patients 
with established RA, especially in the bDMARD group. Finally, 
network graphs were generated to visualize the interactions 
among independent genes (Figure 3B). Notably, the structure of 
the network differed among the groups analyzed, IRGs describing 
different grouping patterns. Networks seem to show a progressive 
change from HC, where a weaker network (that is, with subtle 
links among IRGs) is observed, toward a strengthening of these 
links along the clinical stages, with an enhanced overall degree of 
correlation being found in bDMARD patients, hence confirming 
our previous observations.
Overall, these results confirm quantitative and qualitative 
changes in the activation of the type I IFN pathway in RA. 
Differential profiles of correlations among IRGs can be observed 
according to disease status, hence pointing to certain heterogene-
ity within the IFN signature.
iFn signature as Predictor of clinical 
response in Vera
Next, we studied the clinical relevance of the IFN signature in 
the distinct groups. First, the potential role of the IFN signature 
as predictor of the clinical outcome in untreated, VERA patients 
was assessed. Therefore, patients were prospectively followed up 
for 1 year and disease activity and response to csDMARD treat-
ment (glucocorticoids and methotrexate in combination) were 
registered at 6 (T6) and 12 months (T12).
Although the IFN score at baseline (BL) was observed to be 
increased already in this very early stage (Figure 1B), when IRGs 
were analyzed, only differences in IFI44L and IFI6 were observed 
(Figure  4A). Regarding clinical features, a positive correla-
tion between IFN score and anticitrullinated peptide antibody 
(ACPA) titer was found (r = 0.532, P = 0.034).
Interestingly, our analyses did not retrieve an association 
between the IFN score and the DAS28 at sampling (r = −0.055, 
P = 0.835), but with DAS28 at T6 (r = 0.620, P = 0.008) and T12 
(r = 0.552, P = 0.041). Consequently, the IFN score at BL was 
positively associated with the accumulated DAS28 over 1  year 
(AUC DAS28: r =  0.593, P =  0.025). A multivariate analysis 
including IFN score, ACPA, rheumatoid factor (RF), and gender 
revealed that IFN score at BL may be the only independent 
predictor of accumulated DAS28 [B (95% CI): 12.883 (−0.381 
to 26.147), P = 0.051], although statistical significance was not 
reached. Then patients were grouped according to their clinical 
response at T6 [responders (R), n = 8] and T12 (R, n = 10). A 
higher IFN score at diagnosis was observed in patients who 
exhibited a poor clinical response at T6 (Figure 4B), compared to 
FigUre 2 | Analysis of the associations among interferon (IFN)-responding genes (IRGs) by PCA. (a) Biplot from the PCA (correlation method) conducted on all the 
groups analyzed [healthy control (HC), purple; VERA, red; biological disease-modifying antirheumatic drug (bDMARD)-naive, green; and bDMARD, blue]. Arrows 
represent the original variables. The angles between the arrows represent their correlation. Ellipses are drawn for each group (probability set as 0.68, by default). 
KMO = 0.705, Bartlett sphericity test P = 4 × 10−8, determinant = 0.032. (B) PCA conducted individually for each group of individuals included in the study: HC 
[KMO = 0.695, Bartlett sphericity test P = 1.5 × 10−25, determinant = 0.012], VERA [KMO = 0.734, Bartlett sphericity P = 2 × 10−7, determinant = 0.051], 
bDMARD-naive [KMO = 0.700, Bartlett sphericity test P = 1 × 10−23, determinant = 0.053], and bDMARD [KMO = 0.642, Bartlett sphericity test P = 2 × 10−25, 
determinant = 0.020].
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either good responders or HC. Equivalent results were observed 
at 12  months [non-responder (NR) vs R: 0.17 (0.82) vs −0.44 
(0.77), P = 0.039; vs HC: −0.40 (72), P = 0.003]. This association 
with the clinical outcome was observed when IRGs were ana-
lyzed individually except for IFI44 (Figure S1 in Supplementary 
Material), both at T6 and T12. Interestingly, even in the case of 
MX1, despite not being increased compared to HC, increased 
levels were observed in NR. Next, the ability of the IFN score 
to discriminate between responders and non-responders was 
evaluated by COR curves. Accordingly, IFN score showed a good 
FigUre 3 | Analysis of the correlations and structure of the interferon (IFN)-responding genes (IRGs) networks. (a) Analyses of the correlations among IRG in the 
different groups studied. Correlation matrices were plotted in 2 × 2 correlograms. Correlation coefficients were depicted in white. Color of the tiles is proportional to 
the strength of the correlation (color scale is represented at the bottom of each grap). (B) Network analyses of the IRGs in the groups studied. Each node 
corresponds to an IRG, and the lines illustrate the strength (width) and sign (green, positive; red, negative) of the correlations between each pair of variables. The 
interferon (IFN) network in healthy control (HC) is characterized by a group of three IRGs closely correlated [IFN-induced protein 44 like (IFI44L), MX dynamin-like 
GTPase 1, and IFN alpha inducible protein 6 (IFI6)], almost not related to IFI44L. Stronger correlations were observed in very early rheumatoid arthritis (VERA) and 
rheumatoid arthritis (RA) established groups compared to HC, and a more complex, intricate network was observed in biological disease-modifying antirheumatic 
drug (bDMARD) patients, with a closer location of all IRGs and a strong correlation between IFN-induced protein 44 (IFI44) and IFI44L. Similarly, a correlation 
between IFI6 and IFI44 is differentially expressed in established RA, compared to VERA or HC. Additional information on the network structure and its overall 
activation was summarized in the table at the bottom of the figure.
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discriminative capacity. Exclusion of the IFI44 expression [IFN 
score (3 genes)] from the composite score did not substantially 
change the results. Similarly, a lower but still good discriminative 
capacity was found when only IFI6 and IFI44L were retained in 
the IFN score (Figure 4C).
In sum, a high IFN score at diagnosis in untreated RA patients 
is linked to a poor clinical outcome, thus shedding some light into 
their potential clinical implications as a biomarker.
iFn signature in established ra
Next, an analysis of the potential associations between the IFN 
score and clinical features in patients with established RA was 
performed.
The IFN score was not correlated with DAS28, disease dura-
tion, or RF/ACPA positivity in the bDMARD-naive group. In 
addition, no associations with GC or MTX treatment were found. 
The clinical response of these patients to csDMARD therapy was 
monitored during 1  year, and five patients were switched to a 
bDMARD treatment due to clinical inefficacy of csDMARD 
treatment. The analysis of these patients revealed that IFN score 
at study entry did not differ compared to those who continued on 
csDMARDs [−0.13 (0.89) vs 0.27 (0.89), P = 0.140].
Then the associations between the IFN score and clinical 
features were analyzed in patients undergoing bDMARD treat-
ment (all anti-TNFα agents). Surprisingly, a negative correla-
tion between IFN score and DAS28 was observed (r = −0.358, 
FigUre 4 | Interferon (IFN) signature as a biomarker of clinical outcome in very early rheumatoid arthritis (VERA) patients. (a) Analysis of the individual IFN-
responding genes expression in VERA patients (white boxes) compared to healthy control (HC) (gray boxes). (B) Differences in the IFN score among HC and 
rheumatoid arthritis patients classified as responders (R) or non-responders (NRs) according to European league against rheumatism criteria after 6 months. Boxes 
represent 25th and 75th percentiles, whereas whiskers represent minimum and maximum values. Statistical analyses were performed by Kruskal–Wallis with 
Dunn–Bonferroni tests for multiple comparisons. P values correspond to those obtained in the multiple comparisons tests. (c) Area under the curve (AUC) receiving 
operator characteristic analysis of the IFN score to predict response at 12 months. AUCs, 95% confidence intervals (CIs), and P values are shown in the table for the 
IFN score: four genes [IFN-induced protein 44 (IFI44), IFN-induced protein 44 like (IFI44L), IFN alpha inducible protein 6 (IFI6), and MX dynamin-like GTPase 1 (MX1)], 
three genes (IFI44L, IFI6, and MX1), and two genes (IFI44L and IFI6).
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P = 0.032), but no associations were found with disease duration 
or HAQ. When individual genes were analyzed, MX1 showed a 
stronger correlation with DAS28 (r = −0.459, P = 0.005) com-
pared to the other IRGs (IFI44: r = −0.104, P = 0.546; IFI44L: 
r = −0.384, P = 0.021 and IFI6: r = −0.394, P = 0.017). In addition, 
negative associations with RF titer (r = −0.565, P < 0.001) and 
trend with ACPA levels (r = −0.302, P = 0.087) were found for 
the IFN score. Importantly, no effect of GC or MTX co-treatment 
was observed.
As a conclusion, the IFN score was not associated with the 
clinical response to csDMARD in established RA. Surprisingly, 
opposed associations with clinical features were noted between 
bDMARD naive and bDMARD patients, a negative correlation 
with disease activity being found in the latter. Whether bDMARD-
induced qualitative changes on the IFN signature underlie these 
contrary results remains to be elucidated.
changes in the iFn score upon  
TnFα Blockade
Although a similar IFN score between bDMARD-naive 
and their bDMARD-treated counterparts was found, its 
clinical relevance was notably different between them. Then 
we hypothesized that qualitative changes within the IFN score 
composition occurring upon TNFα blockade may underlie 
these findings. To further explore this idea, the IFN score was 
prospectively analyzed in a group of 13 biological-naive RA 
patients at BL and after 3 months upon TNFα blockade [post-
treatment (PT)].
On the one hand, neither the IFN score nor individual IRGs 
changed upon TNFα blockade (Figure 5A). No changes in leu-
kocytes, neutrophils, lymphocytes, or monocytes were observed 
(all P > 0.050). No association between IFN score and DAS28 at 
sampling was found in none of the time points analyzed. However, 
IFN score at BL was an independent predictor of DAS28 after 
treatment [B (95% CI): 0.577 (0.052–1.102), P =  0.035] after 
adjusting for gender, RF, and ACPA positivity. However, when 
patients were grouped according to their clinical outcome, no dif-
ferences in the IRGs expression levels were observed (Figure 4A) 
(Table S3 in Supplementary Material).
Next, we evaluated the associations among IRGs upon TNFα 
blockade. First, a PCA conducted with IRGs from RA patients 
before and after TNFα blockade (Figure 5B) revealed that inde-
pendent groups could not be identified, which is in line with the 
lack of absolute differences observed. Actually a notable overlap 
was found, similar to that of bDMARD-naive and bDMARD 
groups in Figure  2A. Nevertheless, BL and PT showed differ-
ent distributions, which may be attributed to distinct genes 
FigUre 5 | Continued
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FigUre 5 | Analysis of the interferon (IFN) signature upon tumor necrosis factor alpha (TNFα) blockade. (a) Paired analyses of the expression of the individual 
IFN-responding genes (IRGs) and IFN score at baseline (BL) and posttreatment (PT) with anti-tumor necrosis factor alpha (TNFα) in 13 patients prospectively 
followed up. Patients were represented in red (responders) and blue (moderate/non-responders). Statistical analyses were performed by Wilcoxon test. (B) Biplot 
from the PCA (correlation method) conducted on the—BL, red; PT, blue—samples from rheumatoid arthritis patients. Ellipses are drawn for each group (probability 
set as 0.68, by default). (c) PCA independently conducted for BL and PT samples to evaluate changes in the IRG occurring upon TNFα blockade. (D) Correlation 
matrices and network analyses of the IRGs in the BL and PT samples. Stronger associations among IFN-induced protein 44 like (IFI44L), IFN alpha inducible protein 
6 (IFI6), and MX dynamin-like GTPase 1 (MX1) were found in the BL samples, with a farther location for IFN-induced protein 44 (IFI44). However, a more uniform 
pattern among IRGs was found after TNFα blockade (PT), pointing toward two IRG clusters (IFI44 + IFI44L and IFI6 + MX1). These results confirmed those obtained 
in the PCA and are in line with the findings from the cross-sectional analysis (Figure 2).
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hallmarking each group. In fact, when the associations among 
individual IRGs were compared between BL and PT samples, 
different IRGs profiles were detected (Figure 5C). The correlation 
graphs and the network analyses (Figure 5D) supported changes 
in the correlation profiles among the IRGs and confirmed differ-
ent structural organization of the IFN signature before and after 
TNFα blockade. Interestingly, these observations also paralleled 
those obtained in our cross-sectional analysis (Figure 3).
Taken together, these results confirm that TNFα blockade lead 
to profound qualitative changes within the coordinate expression 
of IRGs rather than absolute changes in the gene expression levels. 
These qualitative changes may underlie the different associations 
observed with clinical features.
DiscUssiOn
Although a compelling body of evidence highlights a potential 
role for type I IFNs in RA, its clinical relevance remains poorly 
understood. This study sheds new light on the type I IFN activa-
tion in RA. Our findings revealed that the IFN signature is present 
already in the very early stage of the disease, and quantitative and 
qualitative changes occur along the disease course. Although 
the type I IFN score at onset can be proposed as a biomarker of 
clinical outcome, a different picture is observed in patients with 
established disease, especially in patients undergoing bDMARD 
treatment. Distinct associations among IRGs paralleled these 
observations. Overall, our results add some complexity to this 
field and suggest that the IFN signature(s) are less uniform and 
simple than currently considered.
An important finding from our study is the characterization 
of the type I IFN signature during the earliest phase of RA. 
Although several studies have focused on the type I IFN signature 
in patients with established disease (9, 10, 13, 14), this is the first 
study where IRGs are quantitatively and qualitatively analyzed in 
a group of untreated, VERA patients, and its clinical relevance is 
prospectively assessed. A potential role for type I IFNs during the 
early stage of the disease can be expected. These findings are in 
line with previous evidence linking arthritis development to the 
use of IFNα as a therapeutic agent (5, 6). In addition, it has been 
reported that activation of the type I IFN program in arthralgia 
patients is associated with the progression of arthritis (23, 24). 
In this sense, our results not only found an activation of the type 
I IFN signature but also go further by pointing to a clinical rel-
evance for the IFN score at disease onset as a biomarker of clinical 
response. Equivalent results were recently reported by Cooles 
et al. in relation to the clinical response to initial therapy with 
csDMARDs (25). However, patients undergoing glucocorticoid 
treatment were excluded from the analysis to avoid a potential 
confounding effect. Then, our findings expand the previous evi-
dence, since glucocorticoid treatment did not interfere with the 
prognostic capacity of the IFN score in VERA patients. Further 
studies are warranted to elucidate the clinical significance of the 
IFN signature in the long term.
Another remarkable finding from our study is the complex-
ity observed within the IFN signature along the disease course. 
The associations among individual IRGs were not homogeneous 
in RA, but differed according to the disease course. Then, it 
seems that the type I IFN signature is not the mere result of a 
global overactivation, but specific expression programs may be 
detected. The identification of the main genes hallmarking the 
IFN signature and, more importantly, the distinct associations 
found among them will be a key to understand the relevance 
of the IFN signature. Although most of the previous studies 
have focused on the first point, less attention has been paid to 
the latter. Interestingly, it has been reported that the overall 
state of correlation and co-regulation phenomena are crucial 
to the type I IFN signature (26). Similarly, Somers et al. found 
prominent differences among IRGs in lupus when analyzed on 
the basis of a PCA, with three clusters being defined by five IRGs 
(27). However, whether a similar picture could be found in RA 
remained unknown. Our approach led us to propose that the IFN 
signature exhibited quantitative and qualitative changes among 
the different clinical stages in RA. Different profiles within the 
IFN signature were observed, suggesting that distinct IRGs (or 
IRGs clusters) were responsible for the IFN signature in each 
clinical stage. This picture may be related to the existence of co-
regulation and co-expression mechanisms within gene expression 
profiles. In this sense, a proper analysis of the associations among 
genes can help to delineate functional biological programs with 
clinical relevance (26, 28), such as the response to a therapy or 
the disease aggravation, hence supporting the need of capturing 
such heterogeneity.
Therefore, it seems plausible that heterogeneity of the IFN 
signature may impair its clinical applicability. This notion 
was proposed in a recent article, where the IFN signature was 
observed to be affected by some csDMARDs, with the exception 
of MTX (14). This is in line, at least in part, with the results herein 
reported. However, our results add to the current knowledge by 
studying the associations among IRGs. Overall, these findings 
may explain why the type I IFN signature was associated with 
clinical features in very early, untreated RA patients, but not in 
those on csDMARD treatment. Similar conclusions have been 
recently published by other authors (25). Overall, it is feasible 
that the distinct profiles of the IFN response observed may be a 
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source of controversy in relation to previous studies. Although 
some confounders, which can alter the IFN response have been 
reported (14, 25, 29, 30), they were restricted to the degree of 
activation. However, this is the first time that a qualitative insight 
is addressed.
An equivalent scenario is depicted in the comparison between 
biological-naive patients and their biological-treated counter-
parts. Despite not differing in their absolute IFN score, divergent 
associations with clinical parameters were registered in the cross-
sectional analysis. Similar results were observed in the prospective 
subgroup. Interestingly, a poor outcome upon TNFα blockade 
had been linked to the activation of the IFN pathway in RA (15), 
although no differences were observed upon treatment, which is 
in line with our findings. In that article, a large interindividual 
variation was observed (15), being attributed to the result of differ-
ent regulatory mechanisms. However, this heterogeneity was not 
approached. On the other hand, distinct profiles among IRG were 
found before and after the exposure to this therapy. Importantly, 
the IFN score was negatively associated with different clinical 
features in bDMARD-treated patients, thus suggesting a potential 
regulatory or suppressive impact of the IFN score in these patients. 
Among the individual genes analyzed, stronger associations were 
observed for MX1, hence pointing to this gene as a potential 
driver of this effect. Interestingly, MX1 is known to be a gene 
target gene of IFNβ (31, 32). Consequently, it may be conceivable 
that bDMARD treatment could be related to an IFNβ-related, 
rather than a IFNα-related signature. Actually, both IFNs have 
been described to contribute to the IFN signature in RA (33, 34) 
and the IFNβ/α ratio has been reported to be a predictor of good 
therapeutic response in anti-TNF-treated patients (33). Recently, 
de Jong et al. have revealed a notable diversification of the IFN 
signature among patients with immune-mediated diseases with 
regards to the ratio between IFNα- and IFNβ-specific response 
programs (18). Interestingly, RA patients exhibited an interme-
diate position between SLE patients (mostly IFNα specific) and 
IFNβ-treated multiple sclerosis patients (mostly IFNβ specific). 
Importantly, MX1 was identified as one of the IFNβ-related genes. 
However, the clinical relevance of this IFNα/β ratio was not ana-
lyzed. Overall, all these findings reinforce the idea that not only 
the degree of activation of the type I IFN but also its composition 
are key to unveil its potential role as biomarker in RA.
In conclusion, our results revealed that the IFN signature was 
not quantitatively and qualitatively homogeneous in RA, but cer-
tain heterogeneity can be recognized. Both the disease course and 
therapies are associated with changes in the levels of expression 
and the structure of the IRGs response in RA, hence limiting its 
clinical relevance. To the best of our knowledge, this is the first 
study where the peripheral blood type I IFN signature, together 
with its clinical relevance, was quantitatively and qualitatively 
analyzed in VERA. Although this work represents a proof-of-
concept study of the type I IFN signature in RA and its clinical 
relevance, it paves the ground for future, larger studies involving 
a higher number of IRG and long-term clinical outcomes. This 
will allow the identification of the best panel of IRGs and the 
best approach to be implemented in the context of personalized 
medicine.
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